Intermittent Fasting, Stimulat…nt with Dr. Francisco Calaveri
Tue, Oct 10, 2023 4:53PM • 1:53:23
SUMMARY KEYWORDS
glp, curcumin, activity, drug, studying, compound, protein, affecting, level, peptide, body, ketones, mtor, fat, activate, research, work, atp, feel, pharmacology
SPEAKERS
Bill Clearfield
00:27
How are you?
00:35
Oh, you can hear me now. All right. Perfect. Thank you for being with us. My pleasure. Thank you for having me. I had a little bit of confusion over over initially over the format. I was told I was being interviewed and then Maria said no, you’re presenting and Okay. Let me just put this together real quick. So here we are.
Bill Clearfield 00:56
You’ve done this before, right?
00:58
Many times. Yes.
Bill Clearfield 01:00
Yeah. So not a big deal. So we have a fun group. They were kind of the outcasts of the real medical world. So everyone’s got a story to tell. So each other so
01:18
I think what happens you know, when people come down this alternative path, it’s because of personal experiences that have kind of, you know, it’s almost like that I saw God that one that one event and it changed my change my belief system, right?
Bill Clearfield 01:32
Yeah, pretty much. Everyone in our group pretty much as some sort of story like that. So yeah. And, but they’re all you’ll find all this they’ll ask you good questions. And they’re, they’re all very interested. So a lot of computer laughter after five. So usually we get started right about,
01:55
so where are you by the way? And Vancouver, Canada. So it’s 5pm. We’re on the East Coast west coast with you.
Bill Clearfield 02:01
Yeah. Yeah. So So I escaped the east coast a long time ago. So many years I’ve been out here I’m starting to get used to it. So.
02:13
So
02:14
so having having lived on the East Coast, and then back here, I find that when, when I was a young man and starting to do business in Toronto on the East Coast and from Canada and then in Jersey, they all they all think that we on the West Coast are a bunch of pot smoking tree huggers. We’re not
Bill Clearfield 02:36
there Jersey worried
02:38
I did business and so when I was when I was about 31, a Toronto company bought one about a company that I had conceived a sports nutrition company after I’d won Mr. Of America and in Los Angeles, and, and the parent company that owned them was in New Jersey. And they so I spent, gosh, one week on every month for two years flying to Toronto for three days in the office there and then to New Jersey for two or three days. Did that for about two years. Got to really, it was an amazing evolution on a month to month basis. Of kind of amping up your personality to deal with Toronto lifestyle and personnel because they’re trying to be like the New Yorkers fast pace I felt like and then I go to New York and it’s no no next level
Bill Clearfield 03:31
will be near New York. Are you down? South South Jersey.
03:36
I was in gosh, where I was in Jersey right near the airport. It was this was like this was when this got to be 25 years ago now. And the company mean, Frankl was the was the owner at the time will come to me again, but it was there a major player in the industry there at the time, I think about a $300 million company 30 years ago. Oh my gosh, why does it escaped me now. Keith Frankel was the was the son of the owner, the original owner, or there were a Jewish family that did so well out there. They’re amazingly successful
Bill Clearfield 04:24
in doing supplements and this kind of stuff for Word and a couple of weeks.
04:30
You know, I gotta tell you, I started out in the in the natural health space. When I was about 22, just in the interest for me was was really performance and I I did my undergrad at the University of British Columbia and human nutrition to better better grasp the fundamentals of nutrition. So that I can you know, take it next level and, and it’s been a long time and you know, the last 1520 years of my more senior life in this in this in this practice, so to speak, has been to try and redefine many of the botanicals at a level of the genome and proteome, using allopathic drug research models to either validate the pharmacology or invalidate it, and then begin to really understand I have some I really believe I’d love to be able to start with a five minute intro on the philosophies on what got me here. So that people really get where I’m coming from from a pharmacological level because
Bill Clearfield 05:28
more than welcome to do that.
05:30
No, that’d be great. Thank you. I see we have some, some participants already.
Bill Clearfield 05:36
Oh, yeah, we have. We usually get anywhere from 20 to 40. So ever depends on what’s what’s going on, uh, you know, time of the year what’s going on in town. And we get folks from all over the country. So and like I said, most of you will be coming in after you know, sometimes up till 530 Quarter to six events.
06:02
Okay. So Well, I mean, if I can start informally to kind of give a background is it this is recorded is it
Bill Clearfield 06:10
it will be in when we start the formal thing, so okay.
06:14
Yeah, so my gosh, it’s been I’ve been in the natural health industry since 29 years now, and more on the medical allopathic drug research arena for the last 20 years. And in fact, I was a I was a mature student doing my experimental medicine PhD work at the University of British Columbia. After I sold my first company that that I used ultimately it was a great sports nutrition company. After I won Miss North American had just finished my undergrad in human nutrition. But my my passion was pharmacological research in the natural medicine side. So I use the funds from that revenue from the revenue that came in all went to doing research. And eventually when I sold the company i i was still still inspired to learn more about drug research protocols. I I went and did my experimental medicine doctorate at UBC and continue to do a second level of that doctorate with an international company in India because they give me access to cancer patients that are very difficult to access here in North American with you know, the ethics boards make making it more difficult, but I’ve been able to work in collaboration with an Indian University. And I can lead into you know why I did that’s because many of the natural medicines that I worked with to study the constituents. So I want to back up a little bit and maybe work into more formally what what we do. You know, we know that in allopathic medical fields. The drug research is designed to develop drugs that are very selective in their targeting of drug targets. The selectivity has great has amazing benefits simply because there’s a it’s just easier to manage the adverse events if there are going to be adverse events, but I, you know, I believe this is a fallacy because you know, when you’re studying particular drug targets, for selectivity, you’re not seeing a lot of the adverse events going on because you’re not looking for those targets. And those are events until it goes into the population and you’re, and you’re affected by the s&p, so you know, nucleotide polymorphisms, that are prolific and in the population. Then you have on the other side of that philosophy, and I’ve been in the middle so I was not accepted by either for a while. You have natural, holistic medicines that are not supposed to be altered from their holistic state because they say that it treats the body in a holistic way that’s designed by nature and has co evolved with humanity and other organisms to deliver a functional medical outcome on multiple targets that are synergistic. And what I’ve said, in fact, going to India, Singapore, and a lot of these countries where I’ve presented our research because we are, if I didn’t mention that earlier, we’re a drug research company. And we use all the protocols that are used and all the equipment that’s used in allopathic drug research models, but what we do, as will isolate each of the constituents in many of these natural medicines to understand better at the genomic level and the proteomic level, how the poly pharmacology is generated by these multi constituent medicines. And therefore, then once we understand how the poly pharmacology is generated by each constituent, then we’re able to engineer with greater specificity and selectivity for indications that we’re looking for based on the targets that are associated with disease pathologies. And so the interesting thing and the last conversation I had in India at a university about seven months ago, and it came with the first 20 minutes of attacks, you cannot touch the holistic medicines because and so you know, my father asked me is this, you know, three to five or 6000 years ago, when natural medicine was used by many of these holistic healers, first of all, you know, we didn’t have the tools we have today to be able to study each of these constituents in a way that we have today. And second of all, the medicines that we’re harvesting today are going to have a different constituent profile than they did 3000 years ago based on the insects that they’re exposed to based on the the soil, the climate, all these things. So why wouldn’t we isolate each constituent and study them selectively? And know, how we can synergistically create cocktails that they say, nature has generated for us with knowledge as opposed to, you know, unexpected understanding that’s passed down over 3000 years, that will have changed in terms of the constitution of those, those those plants. So that’s, you know, my philosophy and that’s what we do here. And sometimes we get amazing hits. Sometimes you don’t, and, you know, you just take the path where you’re getting success, and we further fine tune them in the context of common diseases today. And you know, right now, our focus you know, as metabolic syndrome, insulin resistance and lipid metabolism, to support people on their quest to make lifestyle changes from the outside in, but also instill metabolic, genomic and proteomic prompts. That help people find those metabolic outcomes, coupling them to lifestyle changes. That’s where we are today. I mean, we’ve had my personal journeys based on ulcerative colitis. And you know, I was diagnosed with ulcerative colitis before I won Miss North America. I was hospitalized. They were going to resect my large intestine. At the time, I was taking extremely high doses of curcumin to recover from the physical work I was imposing it was part of the strategy to deliver an anti inflammatory effect so it wasn’t prolonged over time. And when I ran out of this curcumin, it was out there was a worldwide shortage in 92, even before people knew about curcumin prolifically here in North America. And i i A disease that I knew I had but couldn’t pin down it was never diagnosed. It always flare up when I had exams in university. And I just thought, you know, I had a just a weak genetic predisposition for stress but eventually it was diagnosis severe ulcerative colitis. And when I resubmitted and re administer what I was using, it never treated the condition completely. But it took the edge off enough for me to limp along. And so I began to study curcumin the and what people don’t realize is that you know, curcuminoids, even when in their pure extract are made up of three curcuminoids to make the full curcumin extract that we say is a 95% curcumin, and the question I had, because I was getting better results for my ulcerative colitis from the certificate of analysis that showed curcumin three bgmc Vista methoxy curcumin when elevated in that in that total extract produced a better outcome for my condition. And that’s an n of one which nobody could rely on. So I said, Okay, we’re gonna map the pharmacology of each of these curcuminoids and that was that was actually my thesis project. For my PhD. And that’s what and that’s what started this in motion.
Bill Clearfield 13:33
Alright, so let me read a little bit after five now and those of you everybody who’s on here, this is Dr. Franco. Calavera from
13:46
its Vancouver, Canada.
Bill Clearfield 13:50
I know Vancouver, Canada, but your company is
13:53
biologic pharma medical, we were a drug research organization. Yes.
Bill Clearfield 13:57
And you’d make the advanced medical solutions products is that
14:01
we do we will make the products using our patented technologies that deliver that pharmacology we’re about to speak to Yes,
Bill Clearfield 14:08
yeah. So and we’ll we’ll we have a nice offer from Jackie our liaison that will talk to you about when we’re done. So, Dr. calvarium. I’m gonna let you introduce yourself You said you want it to was that your little philosophy you wanted to talk about?
14:29
Yeah, I just wanted to kind of lay the groundwork for you know, where we come from. If everybody I think most of the people we see were on there. I mean, I could do a three a 32nd nutshell,
Bill Clearfield 14:40
to cap it and then move on to that. Because I didn’t get that on. So we record this. We put it on our website. That’s okay with
14:46
you. Yes. Yeah, sure. And,
Bill Clearfield 14:49
and we’ll let we’ll let folks in. We get questions in the chat. Um, do you’d like to do them as they come along? Or do you usually really do them at the end, so we don’t interrupt.
15:01
Yeah, let’s save them until the end, and then we can just collectively deal with them. Okay.
Bill Clearfield 15:05
All right. So thank you really, for coming. I can tell this is going to be pretty very interesting and pretty exciting. And before you even begin to deal with any peptides at all.
15:19
Um, well, the only one we’ve begun to focus on significantly well in terms of of drugs that are peptides related know, where we try to induce peptide activity but not particular peptides other than searching activation, or targeting certain activation, but not peptide drugs.
Bill Clearfield 15:37
Alright, because, you know, that’s in the news this week. So yes. Okay. And then with that, Dr. Calavera. Please take this take the floor and I’ll get out of your way. Good. I gotta
15:49
see where I’m where I’m sharing the screen. Okay, I gotta see where they actually downloaded my hang on a sec here. Oh, here we are. Okay, there we are. So as I as I resurrect this PowerPoint, I want to say first of all, that, you know, I thought I was only being interviewed. I didn’t have a clear PowerPoint prepared. So I pulled up some slides that I had from previous work to create an informal dialogue that we’re going to deliver today. I wanted to repeat what I was talking about, though, and that was and that was, you know, the philosophy that I come from. I’ve been in the natural health space. Since 1990. Is a long time ago. I was a youngster studying my undergrad at the University of British Columbia did my undergrad in human nutrition and biochemistry, the focus at the time for me, as a young man was leveraging this knowledge to to enhance physical performance as much as I could. I was a bodybuilder at the time I had won Mr. Vancouver Mr. British Columbia, Mr. Western Canada, the national championships here I went to Los Angeles and competed in the IFBB wieder pro qualifier, won that but as you know, you know, you begin to escalate in that sport at that level, and eventually, it becomes an unhealthy sport. You start training like that to to feel healthy and fit. And the competitive aspect of it takes over, takes over and you have to make an adult decision at that time. And I you know, for me, the my passion, my original impetus for all of what I did in sport and and vice versa and academics was really accrual of information and knowledge and that’s been my, my focus. See if I can get this PowerPoint to share so the I started out in the natural health industry and conceived the sports nutrition company come combining and congealing a lot of the philosophies that I had, and eventually, after selling the company, because my focus was accrual of information and studying and research, I went back to do my PhD. At the University of British Columbia continued work and it was an international level and phase with an Indian University. And the basis was that I had begun studying and researching Indian medicines natural medicines, and I didn’t I wasn’t interested in studying the holistic approach but more isolation of actives to create a selective element to these poly pharmacological agents and, and we know, in allopathic medicine, you know, we’re taught that selective medicines have a better application and easier application because it’s easier to control the pharmacology. There’s a reduced likelihood of adverse events. But the reality is, you know, I think this adverse events reduction is a fallacy because, you know, when we’re studying a specific target, we’re not seeing what else is happening in that cell in terms of other targets and how we’re affecting health in general and we see that when these drugs go in the population that are affected by the diverse genetic profiles of individuals, different single nucleotide polymorphisms that affect these drugs in different ways. So I began to look at these natural medicines much in the same way that allopathic medical drug models are looking at them. And what I did was I began to isolate each of the constituents in our lab and we have a drug research lab that’s equipped like most or any pharmaceutical lab and will take many of the drugs that are in the marketplace today that are successfully treating many conditions, many people with conditions and then we’ll use those as positive controls in our studies, and will isolate the constituents in all these different natural medicines that create a poly pharmacology to be able to understand how each of them affects certain drug targets and disease pathologies and the genomic Lee how the genome is affected whether it’s a seed elation, or turning on or off various genes that are functioning to support restorative activity and then the idea here is to really understand where the actives are in these natural medicines, isolate them, and then and then regenerate or reengineer the natural medicine so that we’re not only standardizing based on a 95% curcumin for instance, because we all know that curcumin has anti inflammatory activity. What most people don’t get, don’t know from the beginning is that 95% Curcumin is made up of three curcuminoids and although they have significant homology, they’re very similar in structure. There are Shrike there’s there are slight differences that contribute a differential pharmacology. And the question is, you know how, why and what does that differential pharmacology do? If we’re able to understand it? The question I’ve always had is if you are consuming a 95% curcumin Are you or are prescribing it for a disorder that’s inflammatory in nature, from lot to lot in batch to batch, the curcuminoid proportions will change. And if that happens, and they have a slightly different molecular structure, how does that change the pharmacology and so you know that only by mapping the pharmacology of each, and what we did at that time as that actually became my PhD thesis subject matter is studying the NF kappa B signaling pathway, which is directly associated with inflammatory pathology and in the context of these curcuminoids and which, which curcuminoid affected which protein in the pathway, and we found that there are synergistic targets, and if you manipulate the proportion of the curcuminoids so that you’re getting the benefit of all of them towards those synergistic drug targets. The anti inflammatory activity, for instance of that curcuminoid is much more profound than regular curcuminoid extracts. Now, our typical curcuminoid extract will have about two to 3% bgmc for instance, VISTA methoxy, curcumin and the rest of the curcumin content comes from curcumin one deep for Rouleau methane, or D methoxy. Curcumin, and if we’re able to increase the curcumin three level or Vista mythics methoxy curcumin level so that it’s affecting a protein called MSK one and that was one of my discoveries. That led to a patent development and other things in regards to curcumin, were able to enhance the effects of that curcumin, Curcumin is anti inflammatory effect significantly and in fact, so significantly, that it positively affects conditions as profound as autoimmune conditions. And this was the research I did that changed my life. And this is the reason why I’ve taken this path in my life since I was 26. To divert from pure business, to doing the research on these natural medicines because that discovery changed my life. Completely and helped me cope with ulcerative colitis and allowed me to live a normal life with with severe ulcerative colitis that that derailed me in 91. I was hospitalized I lost 25 pounds. They didn’t know what I had. Eventually I was diagnosed and I won Mr. North America a year later, after going back on what I thought was working for me, and and negating the need for for a colonoscopy skill. Sorry, a resection of the colon. And, you know, I’m here today because in doing what I do, because that was my profound life changing event, which taught me you know, there are natural medicines that we know, we know deliver a result. The question is, can we find and isolate the true actives within them to create a selective natural medicine that still delivers holistic activity standardize it to that one selective compounds as well as the 95% curcumin, but also 35 40% Bisti methoxy curcumin instead of the three that naturally exists, and so I took that model and began to apply it over the last 20 years of continued research. On other natural medicines to create selectivity within the medicine that’s supposed to be holistic and poly pharmacologic. Now, I’d like to go into the specifics we’re talking about here, if I can get this thing to share my PowerPoint, and let me see if that’s it. Can you folks see that screen right now?
24:58
Let’s see here. No, we cannot Yeah.
25:03
Okay. Why is it not sharing? Share Screen
25:15
should still see you there we go.
25:32
Fireside Chat. Yep, there we go.
25:53
You heard it there for a minute.
Bill Clearfield 26:17
You can get past here it says your screen sharing right here.
26:36
Looks like you’re also muted
26:53
There you go.
Bill Clearfield 27:04
Alright, an alternative with the email me the slides and I can’t get it work the other way.
27:32
Give you hit cancel here
Bill Clearfield 27:40
except that you’re muted now except that you’re muted.
27:49
Salami to that. Yeah. Okay.
27:52
There we go. Now,
Bill Clearfield 27:55
what does that look? Now? I’m looking at me. I know what everybody else is looking at. I know what I look like you can get it off. Okay, is that is that visible? That’s it. Yeah, there we go.
28:07
Perfect. So, what we’ve done here there are two different technologies that we’ve we’ve combined here, the hunger GLP. One is a separate technology to the thermo GLP one, but they both seem to have independent features. And I have to tell you, you know as we study these technologies for activity, that is that is where for instance, in this case looking for GLP one induction, we look for homology within the structure of various elements and in the case I’m in the case of thermal GLP. I’m going to start with thermal GLP one thermal GLP one was originally studied for its ability to activate thermogenesis thermogenesis most of you are likely aware of is the capacity for the body to utilize energy substrates and in particular here fatty acids or fat to generate heat from those substrates as opposed to having them go down the path in the middle Condrey will oxidative activity. Have them then go down the path to create ATP. Now most of us are born with a significant amount of brown adipose fat tissue. as infants we have a lot of this brown fat that that blankets our organs and sits dorsally to help control temperature. And the idea is that you know as infants, we don’t have the capacity to shiver if we’re cold and that shivering creates the friction needed for thermogenic or temperature control. So infants have this built in mechanism. brown adipose tissue that burns fat as a primary energy source to create heat. Now I’m going to go into fundamental activity, assuming that you folks don’t have this knowledge, but I’m sure you do. So forgive me if I’m going into fundamentals that are unnecessary, but I think we’ll start with that. And we’ll have white adipose tissue that is is usually peripherally fixed that stores fat, it does not burn fat is not metabolically active in the form of burning fat as energy. Although the fat tissue itself is extremely active and considered an organ in the body that secretes a lot of hormones, many of which are precursors and functional as inflammatory hormones. And it’s one of the reasons why with adiposity we tend to be predisposed to inflammatory activity and insulin resistance and things like that. We have within the white adipose tissue that’s peripherally embedded we have what are called beige fat cells that are predominantly genetically wired and prepared to be burning fat as a source of energy eliminating fat from the body. And what’s amazing is that we also have this capacity with the right, genetic and proteomic prompts to reactivate the brown fat that has gone dormant with age. Now some say that the dormancy is caused by the fact that we as we grow older tend to control temperature in different ways. The obvious thing is clothes and our thermostat and things like that. And we don’t need this protection from the environment because we consciously take care of those things. But if we’re able to reactivate this brown adipose fat or the beige, adipose tissue that’s in the white fat we’re able to activate a natural system that burns fat independent of exercise. And I have to tell you guys, I sit with my with a fan right beside my my desk because I’m burning hot all day now. And it’s because we’ve I’ve been using obviously what we what we we tote and toot here. And the fact is that this stuff works amazingly we’ve shown it in the labs. We’re about to publish research, but we’ve held back the research from publication in peer reviewed journal because we’re continuing to add more experimental work that validates what we’re doing. This screen that you see here shows brown adipose tissue that’s becoming active and we’re basically differentiating dormant cells that are the controls in the top left hand corner. And you can see how the white spaces or brain are opening up and you’re seeing that the brown fat is being activated and differentiated. The uncoupling protein which is responsible for uncoupling the process of ATP generation from food substrates. So think about this when our body uses glucose our cells use glucose to generate ATP for energy. We have to work that energy off whether it’s a metabolic activity or whether it’s physical activity before we begin to burn us convert and store the energy as fat. And so in this case, here, the uncoupling protein activation in the brown fat changes the how the proton gradient works in the mitochondria, to divert it uncoupling it diverting it from the generation of ATP to the generation of heat, energy, and that dissipates as heat and you can literally feel that heat within 20 to 30 minutes of taking the product that’s designed for this thermogenic activation. Now, interestingly enough, we’ve been able to go upstream to this effect and show that the same compound activates hormone sensitive lipase. And I don’t see that at all as a coincidence, because when you think of hormone sensitive lipase, it’s primarily exists in the white adipose fat. And moving down to the slide here, where we’re showing some of this activity from the work we’re doing, and let’s see if we can, I don’t know if that’s clear to you. But we’re showing there’s three different targets that we’ve targeted there that we show activity of. And I’m going to hormone sensitive lipase is in the middle, and the compound that we’re looking at is the one in the mauve color that shows a higher level of all of the other compounds. And this hormone sensitive lipase is an enzyme that exists in the adipose tissue. It’s typically activated by catecholamines in the body. Now, I don’t know if you recall, and I think you folks that you are of a similar age of that I am, but there was an era when I was about, you know, between 18 years of age and 25 where there was prolific use of in sport and by people trying to lose weight, prolific use of what they call the ECA stack, and it was made up of ephedrine, caffeine and aspirin. And the interesting thing is that the ephedrine, caffeine and aspirin, affected hormone sensitive lipase and uncoupling protein in a similar way that were affecting it. Except we’re not affecting an adrenergic activation to have a negative impact on hypertension, cardiovascular events, like like the ephedrine would have, like extraordinary extraordinary levels of caffeine would have and what we’re doing here is finding in the specific galleried in the EEG CG that’s extracted from green tea EGCG coupled, coupling that to butyric acid, the short chain fatty acid and the effects are profound if you look at the graph, it doesn’t give you give you a clear indication, when the papers are published, it will be very clear. But the other elements are forms of butyric acid, the short chain fatty acids and different forms of Galite. And when you combine them you get the profound spike. And the combination creates a molecular activation of the enzyme itself hormone sensitive lipase that activates to break down the triglycerides in the adipose tissue. And the the triglyceride degradation then results in free fatty acids that flow into the bloodstream. Now, that’s great because now you have an energy substrate, an energy substrate that can be used up during exercise. But if you’re not exercising, it’s going to get deposited back into fat stores unless it’s being used up by an additional source, such as brown adipose tissue that we’ve activated with uncoupling protein activation to convert the fat into heat, as opposed to forcing it to run down a pathway for ATP production. Which then otherwise requires exercise to expend that ATP, or it gets stored as fat. So you can see there’s an interesting phenomenon here by the same molecule that’s activating UCP and activating hormone sensitive lipase. These are conserved activities in the body that relate consecutively and supportively to fat metabolism and helping the body get rid of calories that doesn’t need and so you know, we went several steps further to determine how is this these how are these compounds affecting the mitochondria? How are they affecting other elements of the metabolism in the cell? We show also in this graph ATP five A, and ATP five A is a subunit of ATP synthase. And when we’re activating ATP five A are showing that in the cell, we’re increasing the amount of this protein we’re indicating a couple of things are indicating that there’s more activity in the mitochondria, and we’re it’s indicative of mitochondrial biogenesis and it mitochondrial biogenesis is exactly what’s happening. In the brown adipose tissue. We’re increasing uncoupling protein, increasing the number of mitochondria so that we’re creating a Fat Burning Furnace in that brown fat that you’ve all had idling for decades because you haven’t required it. It is the same activity we see occurring when you fast and when you cold plunge. So when you put load on the body in the form of cold plunging, there are various things that happen. And one of the things we began to do is study which proteins are activated during cold lunch that are implicated in the restorative and recovery that people claim there they are achieving. We’re finding that this compound is affecting the sirtuin proteins which is upstream of this and I’ll talk about that in a moment. But affecting many of these same systems to improve the body’s capacity to cope with that cold plunge to cope with the cold and protect the body from an increase the temperature of the body against that cold. So the other thing that you’re gonna eat that you’ve seen that that we show, in summary here is that we’re activating mTOR and mTOR is a molecule is a protein kinase that functions to improve anabolic drive and anabolic drive in terms of lean body mass activation. It’s also involved in the activation of other activities in the cell that involves anabolic drive. One of the negative or adverse events that we’ve seen with semaglutide or GLP. One agonists, we’ve seen mTOR inhibition. And I don’t know if you’ve seen or heard of a lot of the adverse events in the field with GLP one agonists and one of them is the wasting of muscle mass, that as much as 1/3 or more of the weight loss is attributed to loss of lean body mass. And that’s not likely a great thing. Although there are some people that require the support of a GLP one agonist, the reality is that these agonists are synthetic GLP one peptides and the GLP. One peptide itself doesn’t have the same negative effect on mTOR, the endogenous GLP one now semaglutide The synthetic GLP one peptide has various amino acids that have been replaced and that is the way that you would do you would have to develop the peptide in order to to qualify it for patent status. Nevertheless, when you change out the peptides in these when you change out the amino acids in these peptides, you change the configuration, the three dimensional configuration and how they’re going to function on receptor sites. And so it may work for some and it may not work in others. In this case, we’re showing that it does inhibit in fact inhibits mTOR activity and not might be one of the mechanisms that that relates to the muscle wasting that semaglutide and other analogues like it are inducing in terms of the weight loss. So in the long run, what will happen with a lot of those patients if they’re on it for too long, if they lost too much lean body mass it will become very difficult for them to maintain the body mass that they have after they come off the drug. Because the lean body mass won’t be metabolically active the way it was before to help burn calories. Nevertheless, you know I’m not against I’m not one that pins myself against pharmaceuticals versus nutriceuticals. Um, I believe that there is a place for GLP one for those who require it. But in creating the window of opportunity for them to make lifestyle changes that support long term, long term recovery and restoration. We’re showing with that thermal GLP one, we’re activating cert proteins to sirtuin proteins, you’ve probably heard of the serine proteins are seven of them. They are involved. They’re the latest craze in in in anti aging and recovery and restorative activity in regards to metabolic syndrome, glucose management, I think this the certs are an amazing channel and amazing way to restore genomic activity to default stages where for when we were younger. They’re known to de assimilate various aspects of the genome that have become acidulated through epigenetic activity, and that affects then genomic activity that should be restoring tissue and then begins to falter in, in in terms of restoration. So we’re now looking deeper at the sirtuin activity that we’ve been able to identify. There are different sirtuin proteins, some of which are in the cytosol somewhere in the nucleus somewhere in the mitochondria. And they have they pretty much for the most part are involved in restorative activity. So the research that we’re doing on these compounds, although we’re finding some amazing targets that are extremely positive in terms of metabolic health, we’re still in that research process, redefining many of the other activities and new activities that we’re adding to a research paper that’s been evolving. And we were going to need to stop shortly and so that we can publish this paper, but we continue to find new things that I believe may may cause us to migrate into a second paper. Otherwise, we’re never going to be able to publish this. I’m going to move on a little bit to to the hunger GLP one agent and because we were studying the hunger, the hunger product, this is an amazing product that we began to develop as a natural sweetener because we needed to use a substance that was able to sweetened protein powders, sweet and other compounds that we’re making beverage mixes with, but would be able to mask the off notes of many of these natural compounds and this itself is natural to and then we notice that there’s tremendous appetite suppression and various aspects in how we’re feeling when we’re using this compound that were similar to the thermal product. So we began to study it at a molecular level to determine if it is enhancing GLP one, and sure enough, it does show that we’re enhancing endogenous secretion of natural GLP one, and that’s the difference between semaglutide and what we’re doing here. The challenge is that we can’t count on quantifying precise levels of GLP one in each of the patients because people will produce it in variable levels. And when you’re using a synthetic injectable, you’re able to quantify delivery. And in this case we’re inducing GLP one activity which which varies from individual to individual. However, the effect is tremendous because it does help people right away through GLP. One induction control appetite, and we’re also showing that it helps to support the secretion of insulin similar to what many insulinotropic drugs do we’ve we’ve tested it against many insulinotropic drugs including in this particular study
46:23
we’ve we’ve tested it versus on three over three different drugs to show an insulin genic activity that was significantly higher. And here we’ve got something that has zero carbohydrate content, zero protein content, zero caloric content and and delivering a sweetness that is as sweet as sugar if not, if we use it a full concentration between five times to six times sweeter than sugar, but what I believe is formidable about this compound is the fact that you can sweeten a coffee, you can sweetened tea, but you’re getting an effect that’s pharmacological as well. And we have to be careful to differentiate variations of this because as soon as we start commenting on the GLP, one induction, we can’t even use the same compound that we’re using in the sweetener in terms of the nomenclature, because now we have a drug versus a sweetener agent. And and we can’t claim that each one will do both. We have to say here’s a sweetener that helps support appetite suppression, then the other one will be you know, here’s a compound that will induce GLP one if you put it in your coffee. So it’s kind of a play on words, but that’s, you know, we have the same compound doing the same thing, helping to sweeten an agent without the carbohydrate content and the caloric intake as well as inducing GLP one. We can put this in a tablet we can put it in a capsule, we’ve decided to put it in a powder so it’s convenient for people and it gives them something that tastes like candy that they can replace sugar with, and therefore get and then in addition get a pharmacological effect that’s beneficial. What we’ve done in a nutshell here is to devise a system that supports metabolic shift in the body that has the body improve, improve the lipid metabolism, and work towards using lipids as a primary energy substrate. Now there is something that is quite phenomenal about this that I haven’t talked about and I don’t see we don’t see any research displayed about it and we will be finalizing the research on it so that we will have functional data. And that is that this compound the thermal product, the one I started with originally see if we can go back up there. This thermal product not only does it activate uncoupling protein and hormone sensitive lipase, but we’re showing that it induces beta oxidation as well and beta oxidation is the process by which the liver will take endogenous fat and generate ketones from it. And now this from a medical standpoint, and allopathic medical standpoint, the ketone generation is a red flag, because we know that you know, ketoacidosis is a potential problem, especially for type one diabetics. And so we recommend, you know, type one diabetics that can use this product. You just have to keep an eye on your ketones, they’re not going to escalate to deleterious of levels, but just out of safekeeping and out of being diligent and responsible. You know, we say just type one diabetics beware because of the the, the, the access and the regulation of ketones. In type one diabetics is broken. And so in everyone else, and even type two diabetics, they don’t have to worry about ketosis because that’s not really a problem that occurs the body can still regulate keto Genesis. But what we’re doing with this and why this is great, the beta oxidative activity is that beta oxidative activity is what contributes in large part to the appetite suppression that occurs. See, if you go on a diet that is low calorie and or low glucose, the body can still function without a problem to use fat to generate ATP in the peripheral tissues. It’s the brain that pushes you to eat carbs, that gets you into starvation mode, and forces most people who tried to get on to a ketogenic diet forces them to fail, because the brain says I need glucose. I’m going to die without glucose and you need to go out and get me some glucose because fat cannot cross the blood brain barrier effectively enough to be able to serve the neurons with an ATP substrate that’s functional. The second thing is that most people who are aging begin to develop various degrees of what you’ve likely heard of type three diabetes. And type three diabetes is usually associated with dementia because advanced state of dementia, whether the type three diabetic state is contributing to the advanced stage of dementia or dementia itself is contributing to the advanced state of type three diabetes. And again, I’m going to speak to fundamentals which you already know I’m sure, but the type three diabetic state is related to blood glucose mismanagement or insulin function or insulin resistance in the brain. And in that state, the neurons cannot effectively utilize glucose because insulin signaling is not functioning in the brain. That’s the type three diabetic state and so in late stages of dementia when type three diabetes becomes a serious problem, that’s when you begin to see apoptosis and severe and deleterious effects with with regards to recall and memory events. And so, once apoptosis begins to set in large and significant levels, then you know, the the mental state becomes significantly worse fast. And, and in in thing the prognosis is very bad. But if we can prolong energy substrate availability to the neurons, then the brain survives for a much longer period of time effectively, even in this type three diabetic state and or dementia. And so this is not me speaking, but this is the research speaking. And so what we’ve seen is that if you induce beta oxidation, I’m circling back now to beta oxidation, to have the body convert fat into ketones. The ketones then, are small substrates. That are water soluble and can penetrate through the blood brain barrier to serve the neurons with an energy substrate that’s much more efficient in terms of ATP generation for the neurons. In fact, it said that the ketone can supply in excess of 38% more ATP in the conversion to ATP in the mitochondria, then glucose can in the brain. That means this is one of the reasons why people who are on ketogenic diets or are taking exogenous ketones claim that the room is brighter and they feel more cognitively capable is because the neurons are getting more ATP. They’re functional, they’re alive, they’re rocking, and the ketone assimilation by the neuron is independent of insulin function. So if type three diabetes is a significant problem, then the ketone can still penetrate and deliver it’s it’s it’s plethora and wonder of carbon, so that the the mitochondria can generate ATP from that and not need glucose whatsoever. So how does that translate into appetite in the brain driving? Food cravings Well, if the brain has significant ketones to serve its needs for ATP generation. It is not starving. It is happy, it is healthy, and you can go on then this lower calorie diet and stay fasted for a much longer period of time, because we’re facilitating keto Genesis. Here’s one of the challenges with the exogenous ketone versus induction of endogenous keto Genesis, when you take an exogenous ketone, and that’s becoming quite popular, and in fact, it’s a great therapeutic product for people in late stages of dementia or people who are epileptic even because we know that that’s how that’s how this story started was treatment of drug resistant epilepsy. That ketones serves the brain and calms it down and and and provides a healthy energy source independent of insulin function, and the brain is happy and you’re able to stay in a fasted state and the body then the peripheral tissues of the body will be happy to use fat as a primary energy substrate in that state. So
55:04
I guess, you know, I’ve covered a lot of ground in terms of different drug targets. And what I want to iterate is that I don’t want to create confusion or a mishmash of different things happening. I want to highlight the fact that, you know, what we do here is we try to compartmentalize and isolate the actives in these different botanicals, and then we’ll standardize them based on what we know the active should be. And in this case, what we’ve done is gone upstream and downstream to different targets associated with lipid metabolism and determined that it’s not a coincidence that all of these targets are being activated by this compound. You know, green tea, for instance, has been known as a weight management product, but how many people have really gained functional activity from EGCG. And in this case, what we do is we’ll take a specific Galite from there that we know is functioning couple it to butyric acid because butyric acid targets the same, being a completely different molecule still targets the same drug target. And when we show them together, they’re compounding in effect, and we’re showing that biologically we’re showing that in the lab. We’ve shown that in the population, the next step for us now is to publish the pharmacological paper, and we’re already in the process of funding the clinical work, and we’re going straight into clinical research to treat Type Two Diabetes. Even pre diabetic states of insulin resistance we’re targeting and lipid metabolism for the management of obesity. So that’s how these products will be used long term. Again, we’re already demonstrating the pharmacological effects. I think the big next step now is we go clinically, we have to manage the fact that by doing the clinical research, we have to be very careful with the targets we’re targeting and studying. Because we could easily be classified as a drug once we go those steps. So natural agents doing drug like activity based on our evolution of the research and we’re quite proud of what we’re doing here. We’re a bit of an island but I think we’re showing the value of the pharmacological work and and the approved medical solutions are really put faith in us and I believe that that with the right people in place advancing these to the right, the right patients, we’re going to see some amazing lives change. So I don’t know how. Let me see if we have some questions that we can target. Am I visible Am I audible? Is everything good? Yes, you are. Great. That was great. Thank you.
Bill Clearfield 57:59
Thank you for all of that information. It’s going to take a little while to digest that I anybody have any questions?
58:11
Yeah, hi, this is yeah, this is that that was a fabulous discussion. Was this the work of several Choa with the uncoupling protein.
58:25
This work the uncoupling protein originally that uncoupling protein was discovered and actually replicated in 1965.
58:36
Was the Dr. Oz Show? A Nobel Prize for this is one of my favorites. I’m not sure it was him. That’s when he got the Nobel Prize. For
58:45
this. Is that right? Yeah. Several. I’ve seen a lot. Yes. I’ve seen a lot of his work. I wasn’t I didn’t realize that it was his his discovery.
58:55
He got the Nobel Prize for that. Because
59:01
I think this is the future of metabolic syndrome restoration. Because with the activation now here’s the interesting thing. And I’m not sure of the mechanism because it’s never been pinned down and we’re trying to find it with the activation of uncoupling protein. There’s an there’s an immediate positive effect on glucose management. And we’re not seeing the uptake of glucose in that brown adipose tissue beyond normal beyond eight. That’s a typical, but there has to be either an uptake of blood blood glucose or a reduction in the synthesis and production from gluconeogenic amino acids in the liver. So that’s the next phase for us to study.
59:46
That was a beautiful, beautiful discussion. Really beautiful. Thank you.
59:50
Incredible. Thank you. Yeah, I got a second that just impressive work.
59:57
Hey, we’re having fun now. Hey, thank you. Hey, can I have support like that? Nah, man, you’re you’re amazing on the lecture, but I was gonna ask before I got rude. I found some semi nude pictures. You cannot put them up. Ah,
1:00:19
don’t hold that against me. Alright.
1:00:26
So we can see how intense this guy is.
Bill Clearfield 1:00:29
I actually saw them so I didn’t realize that was you though.
1:00:33
Oh, Holy mackerel. Hey, yeah. Aside from that, what you gave us tonight was top class 100%. We thank you very much. You’re on very thin here. It’s very seldom you know, we have all you said since 1990. Most of us have been around since 1990. And what you’re talking about now is major stuff big breakthroughs that happens once in a while and I think you made it. Thank you. Now I’m going to be in touch because they have all these diseases. And we’ll use me as a guinea pig. Thank you, John.
Bill Clearfield 1:01:15
You say the same thing every week. Hey. Even when we had Dr. Siegel, the veterinarian on Yes. You said you had those those.
1:01:26
Now, you know we got we got three lines of stem cells now and are with our group. And it’s all fantastic. And with what you presented tonight, it’s all on the same page. It’s big stuff. So thank you very much. It might save my life. Let’s try it.
1:01:43
Thank you. My pleasure. Thank you.
1:01:46
I’m honored. Thanks.
1:01:49
So um, what
Bill Clearfield 1:01:52
can you give us a little regimen maybe with the products that you showed us on how to use them?
1:01:59
Yes. So typically, I’ll tell you what I do. And I think so. I’m have a body weight of approximately 190. And I stay relatively lean. I have to tell you, if I if I stop using it, and I keep my lifestyle, the weight, same way nothing changes. I start to see the weight come on right away. So this is kind of a countermeasure that has a significant effect. And you know keeping the keeping lean body mass up and body fat down is a tremendous marker for preserve it present, preservation of age and metabolic activity. It’s not it’s not it’s not the you know, the the functional final indicative marker, but it’s one. What I do is take two in the morning to thermal GRPs in the morning with breakfast or without whether I’m fasting, and then I’ll take two in the afternoon around two o’clock. I’ll use the hunger GLP one in my coffee or tea. I’ll use it again in you know, I’ll take a flask of water that may drink twice, say approximately a liter and a half of water a day. But I’ll have three or four doses of the hunger in that that I sip on and that gives it a nice little sweet edge, but you’re getting a constant sip of something that supports insulin function and cognition and you’ll find that you’re just sharp all day, really sharp and full of energy full of will full of drive. Sometimes a little bit too much drive a little bit push but you feel great all day. So if you have a flask of water that you drink all day, put some of the GLP the hunger GLP one in it. One or two doses and then two capsules of the thermal in the morning, two capsules in the afternoon and you’re set.
Bill Clearfield 1:03:53
Okay, great. There’s follow up questions. And there’s Jackie’s phone number there in the chat 831-915-5534 And there’s their email address. For information on these products and mentioned us and I think there’s a little bit of a discount.
1:04:15
So that’s 10% off. So to get the 10% off you just have to go to prove medical solutions.com register as a practitioner and then you will have access to our site and be able to get everything at wholesale prices and get these products. And like we said if you use the code integrated at the end at checkout, you’ll get an extra 10% off the wholesale cost.
Bill Clearfield 1:04:45
Okay, there you go. Okay, well, thank you so much. And with the
1:04:51
Can you repeat the phone number Please miss the phone number. It was all mumbles
1:04:57
it’s right here in the chat is in the chat box, but it’s Eric 83191555340. There it is on the screen.
1:05:10
Thank you, of course. Yeah, all right. Well
Bill Clearfield 1:05:19
Calavera was really can’t thank you enough. This was great.
1:05:24
Thank you. Those of you that are not working. We’re looking forward to to seeing your, your publication as well as the place to that, you know you’re heading towards.
1:05:39
Yeah, well, we’ll keep you guys posted and let you know, we just just had a just had a paper from our organization published two weeks ago and cancer paper that’s in peer review right now that’s just about to publish. So we’re very active in different areas, and hoping to make a difference in in the community and in the human population.
1:05:59
All right, there’s Dr. Patel, how do you use this for cancer patients?
1:06:06
Well, the cancer work was done on a different compound, not this particular product itself. So we haven’t been studying this one in the context of cancer.
1:06:21
What do you use for cancer?
1:06:24
The work we did was in was one of the fractions from a patented ashwagandha extract. Now we know that ashwagandha has positive effects on various types of cancer. What we did was we isolated one of the 35 with analyze to determine it was the one and we punched cancer real hard at full capacity. And we were very effective with with the treatment and the papers just just about the Publish. We have to just change some formatting for the publication and we can send you a link to that it shouldn’t be more than a couple of weeks before it’s ready and published.
1:06:59
That’d be fabulous.
Bill Clearfield 1:07:01
Would be great. Yes. Thank you. And we can put it on our website if you want it so we can
1:07:07
share the word yes. Did you thank you.
Bill Clearfield 1:07:14
Anybody else have any comments questions? Dr. Quinn, you’re awful. You’re awful quiet tonight.
1:07:27
Yeah, my mind is going to this cancer thing like Dr. Patel said that. Well, you know, when we just look at the very beginning and say that that glucose just feeds cancer like crazy. Now we have a way to kind of bypass that I think this is more than a breakthrough. This is amazing.
1:07:48
Well, the one thing you know, you’re right, glucose is is an issue. I think one of the things we plan on doing when we do the clinicals with the cancer is to cut the die ketogenic diet which is facilitated by this product that you guys have here today. You know, when you’re increasing beta oxidative activity, you’re serving the brain, which allows people to fast during treatment, chemotherapy.
1:08:15
Yeah, exactly, exactly. This This goes along with fascinating
1:08:20
crazy cool, yeah. Let me just, yeah.
1:08:27
Have you seen the GLP one agonist, increasing the recurrence of cancer?
1:08:36
We haven’t seen that but I have to tell you something that I found to be interesting, this is completely theoretical. In the context of mTOR, you know, some of the some of the cancer agents are looking at inhibiting, inhibiting mTOR because mTOR can be facilitative of anabolic phase in cancer. So if if, if the GLP one agonists that are synthetic or inhibiting mTOR they would, they would ultimately become candidates for cancer. Treatment.
1:09:17
And again, that goes in with time restricted eating, which will also inhibit mTOR. So it all
1:09:24
together. Yeah. So
1:09:26
it promotes then it’s like anti inflammatory. And is it anti inflammatory?
1:09:38
There’s mild anti inflammatory effects to this product for sure if we ran the test, but not nearly as effective as you’d get from the curcuminoid technology that we’ve developed, we actually developed a curcuminoid technology that’s coupled to turmeric and we call it curcumin. That is just we just patented that and that has extremely potent effects on BDNF, which also helps restore metabolic syndrome helps prove restoration in the brain. And it’s an effective agent against cancer.
1:10:15
Have a patient who was in remission for breast cancer, and she used the GLP one agonist peptide and she lost considerably about 30 pounds of weight. But her white cell count was little high and 27 point 29 marker is little high. So there’s a question that was that because of the using the GLP one agonist or was it from something else?
1:10:54
Well, that’s the one that’s very interesting, because I’ve said if you take a natural peptide and you alter the amino acid sequence of the peptide, what does the body do? If it doesn’t recognize the peptide, it produces antibodies against it and eventually begins to inhibit the activity of the peptide. In order to generate antibodies in an adaptive immune phase. You’re going to see a white blood cell count originally developed.
1:11:33
Like this, this in this patient, and the if still sticks she takes or he takes the peptide as a lesser amount, which still works. So so it’s not building the antibodies and it is ineffective. It is just a question. They haven’t noticed that. It does. Some degree of immune suppression or there is a problem with the immune parameters.
1:12:07
Well, it’s, you know, I think there’s a lot of unknowns we have been studying GLP one agonists in terms of many of these different targets. When we discovered different things like we discovered this mTOR inhibition, it doesn’t necessarily going to translate immediately into a disorder. It just really raises a flag. And you know, when you talk about immune system, white blood cell elevation is what you said originally, I thought I mean, that would make sense in terms of a peptide that’s foreign to the body.
1:12:43
But it was it was more neutrophil elevation, and we’re down. So it was it was not the other way around. Okay.
1:12:56
Interesting, ya know, at this time, we’re kind of theorizing we don’t know a lot about this GLP one and how it’s going to affect the body long term. This is one of the problems a lot of these synthetic chemicals. I mean, I think I’ve said many times and I’ve done some posts. I think there’s a lot of people that can benefit tremendously from these, these, these agonists that are synthetic, but they should be used as windows of opportunity to create the opportunity for the body to restore and to apply lifestyle changes that give people the tools then to restore physical health, as opposed to a long term dependency, because of the loss of lean body mass is going to eventually eventually cause significant problems for most people.
Bill Clearfield 1:13:43
That seems to be one of the complaints about all of the GLP ones that causes muscle loss. muscle wasting, yeah,
1:13:54
gi blockages, but the muscle wasting is why you know we studied mTOR and then we saw in our lab that mTOR is being inhibited by that by the semaglutide and that’s likely the mechanism for muscle wasting.
Bill Clearfield 1:14:08
Any any suggestions about getting around some of those issues or?
1:14:14
Well, you know, I think even our technology that we have being an mTOR mTOR agonist itself that enhances mTOR activity. We’ve we’ve been using it with a lot of athletes who are looking for recovery from training, and it restores muscle I gotta tell you like it. I say this, with with all honesty when I went to in the last two years of my career in bodybuilding, when I went to the Mr. North America, I did anabolic steroids because that’s what you had to do in order to compete at that level. And that’s the reason why, you know, after winning I thought to myself, My gosh, I’m going to do this to continue this this. I’ve reached a point where this is not healthy anymore and pulled away. But I gotta tell you, this product does improve mTOR activity to the point where muscle tone and strength increases for athletes, and works quite well at high doses. But you have to increase the protein intake to accommodate for that growth, otherwise it won’t happen.
1:15:10
Yeah, I was just gonna ask that do you in order to maintain the muscle mass using this? Do you have to really go like one 1.5 grams per kilogram or something like that in the protein one
1:15:21
gram per pound, one gram we only have one gram per pound of body weight which we had 22 athletes 22 actual bodybuilders increased protein to one gram per pound and take triple the dose of this and they all all increase muscle mass. Every single.
Bill Clearfield 1:15:43
A lot of protein though.
1:15:45
It is impossible to do with the regular food impossible. You have to stop you know I had I did it. Three protein drinks a day plus food Okay,
1:16:02
have you tried
1:16:03
using a protein source that that uses, you know, the upwards of 90 plus percent net nitrogen utilization so that you don’t have to consume as much protein.
1:16:25
While there are strategies, you know the amino acid the essential amino acid profiles that that I did not use those strategies. I kind of went back to what was you know, we did what we did conventionally, but that might be a way to improve nitrogen retention. With a lower level of protein.
1:16:46
For sure. Okay, the the I just was thinking that would probably be the only way most people could consume that kind of protein volume. She’s
1:17:02
it’s quite a task. You know, it’s you know, three big meals and three big protein supplements a day. At my age. It’s not something I really wanted to do, but I needed to test that we did it for 90 days. And once I was done, I was like, that’s it. I don’t want to see protein again for a year.
Bill Clearfield 1:17:16
So if anybody there are quite a few pictures, pictures of body builders with your name on it on Google images is that that
1:17:33
I didn’t realize that well.
1:17:36
I gotta tell you, you know it’s funny thing. My I’m divorced from from my five years ago when my girlfriend today I’ve been with her three years she I see these pictures on the internet that you have to be an imposter because I don’t even recognize that guy. Because I would never know that was me. I don’t even look anything like that today.
Bill Clearfield 1:17:57
You’re right. But so what kind of aid would you have had if you if these were available when you were when you were in the bodybuilding world?
1:18:13
Well, I gotta tell you, I was very creative, and I was very studious. We studied a lot of we did use essential amino acid pills. Now the interesting thing is that we see these essential amino acids and the profile of which are shown to increase nitrogen retention. When I was a bodybuilder and you know, young man, I think I was at that time 2122 years of age just preparing for Miss North America. We were using amino acid capsules because the freeform amino acids to consume them in a powder. You may or may not know it tastes like vomit because it’s like pre digested food. And we also used butyric acid which is a short chain fatty acid in combination with them in high doses. And to gag that stuff down was terrible, but it did what we’re seeing today in a lot of the research that has been resuscitated to create formal data to demonstrate that nitrogen retention today. Okay,
Bill Clearfield 1:19:11
well that’s that’s part of these formulas, though, isn’t it?
1:19:16
Well, no, you know, a lot of what I’m doing today, yes, is centered around butyric acid, but it’s actually using compounds that work synergistically at a sub cellular level. To to to, to further to further activate what we’re trying to activate. It’s done at that time. We did it based on what we read what we saw other athletes doing today. What I’m doing is studying them at a sub cellular level to fine tune these so that they’re functional and validated.
Bill Clearfield 1:19:51
Okay, where does your nitric oxide product slowly fall in line with these other two?
1:20:00
We are studying nitric oxide but these these folks have a different nitric oxide come in. It’s quite quite phenomenal. I don’t know a lot about how and what they’re doing. But I know that the results have been quite quite incredible in terms of nitric oxide where we’re showing Enos activation in different ways, but this product they’re using has been in the marketplace that they’re functioning with for a long time. Very effective. I’ve used it and I love it.
Bill Clearfield 1:20:25
Yeah, we’ve been using it also. So I’m just trying to sort of, you know, place place each one. We’ve had a very successful weight loss program here using the GLP ones. With some combinations and now the FDA has decided that the one of the one of the ingredients is now illegal. So we’ll be looking to to alter our plan. So just so you know, all the peptides are gone now, folks.
1:21:03
While the peptides you know, if they’re especially if they’re synthetically derived, I mean, they’re suddenly going to be looked at as food as drugs, right.
Bill Clearfield 1:21:11
Yeah, it seems a kind of a convenient Well, you know, it can be conveniently there’s all sorts of problems with them that some of us have been using them for 1520 years. I never once saw issues that they brought up as complications, so I don’t know, you know? So anyway,
1:21:34
I know, it’s an ongoing cycle.
Bill Clearfield 1:21:38
So, anyway, yeah. So that’s, uh, that’s Dr. Burgesses domain there. So right, John?
1:21:47
Yeah. Well, can you tell us what has been approved as a is approved by FDA now? In the which ingredient is an approved?
Bill Clearfield 1:21:59
Unit? You name the peptide at the FDA.
1:22:02
You were just mentioning about GLP agonist.
Bill Clearfield 1:22:07
Now. Well, the one I’m talking about that we’ve used with it as being BPC 157, but it’s just about just about all of them IP and morale and CJC 1295 G HK cu KPV Dr. Dr. Colossus favorite KPV Simon says the FBI motions
1:22:34
in all of them. So what is their status now?
Bill Clearfield 1:22:38
The FDA has ordered the compounding pharmacies to not not not manufacture them anymore.
1:22:44
And what what are they manufactured? They can still sell? No.
Bill Clearfield 1:22:51
So, you know, we’ve been using these for years and years without, you know, pretty successfully to you know, we we have stroke protocols and
1:23:02
probably that drops down
Bill Clearfield 1:23:05
that’s probably it but anyway, so we’ll we’ll will soldier on as always.
1:23:15
Yeah, that’s one of the challenges that we have and we have to always you know, as we find new new discoveries we have to determine how they’re going to fit into into the regulatory process and not be not be tagged as new drugs. And so that becomes that we have for example, our curcumin product here in Canada and FDA, if we go over 50% EDMC it’s a drug because of the effectiveness on NF kappa B signaling. So we have to do clinical we got approved for COVID and respiratory disease clinical trials for the one over 50% Everything under we are fine over there.
Bill Clearfield 1:23:55
So you have to deliberately make it ineffective. Was that it? Well, we
1:23:59
have to deliberately make it not as effective as the drug version other otherwise it will get it will get tagged and flagged. And then the challenge is, you know, we have to do a clinical trial to demonstrate the drug activity on the indication, and that will be a drug forevermore when it’s actually naturally derived and engineered to be it’s kind of a it’s it’s really sad.
1:24:22
But it
1:24:24
you know, you play by the rules or you or you don’t get to play,
Bill Clearfield 1:24:29
right. So, here we go. Here we go. Again, guys, and gals. So, anyway, Okay, anybody else have any comments or questions? Let’s see what’s in the chat here. Here’s the here’s the list. AOD 990 604. BPC 157 The pitha lawn CGC quote 95 dsid and Kasich 677 kisspeptin KPV Mazzi si LAC and SeaMAX. So most Alpha wandered by most of beta four they got rid of them during the during COVID along with cerebral license so don’t know we’ve used them for ever in a day
1:25:23
that’s
1:25:24
bad. That’s sad. You know, it’s funny these pharmaceutical agencies have themselves been giving given regulatory, self regulatory parameters that I think is very dangerous, very dangerous, and we’re seeing that play out in terms of COVID and everything else but not sure how we can how we can combat that we’re kind of stuck with what they give us.
Bill Clearfield 1:25:49
Yeah, well, we like I said, we soldier on we do the best we can. Yeah. You have any little summary for us there. Dr. talebearer.
1:26:00
Well, I’d like to say what you know, I think I know many of you realize that. I think there’s there’s so much to mine in nature so far for therapeutics, that is just phenomenal. We were just inundated with we are inundated with opportunity. I just hope that we get more researchers that are brave enough to to do what we do without worrying about how other people and other organizations target us. But you know, I say the science the data will speak volumes and the data has been managing and guiding and navigating what we do. We don’t try to go by. We don’t try to theorize we just try to follow the data. And hopefully it leads us down the path of of life changing events.
Bill Clearfield 1:26:48
When when we start using some of these, some of your products, how soon what kind of changes can we can we anticipate how soon do we do we notice an effect is are there obviously it’s dose related? I’m certain
1:27:09
so yeah. So you’re right, it is dose related and what we find for the majority of people who have a reasonably healthy lifestyle, for example, on the brown adipose tissue side, when you take it, within hours, you’re going to feel body temperature go up because the brown fat is mildly active, and you start to stimulate the active brown fat while the body begins to convert and differentiate the rest of the bar brown fat, and over time you start to get warmer and warmer. For a lot of people who are obese. They may not feel that heat increment for weeks because it’ll take several weeks for that brown fat. To differentiate. However, everybody feels the cognitive effects right away and that’s because of the beta oxidative activity that’s immediate, and begins to convert fat into into the ketones and then the brain gets a complete light up right away. And that is what gives you the drive and the capacity to begin to make lifestyle changes because the mind was is going to work with you towards your goal. And you’re able to have to generate that will and the drive to make change. So you start to feel that right away. Within hours you start to feel the brain light up the rooms brighter. And you feel really good. A lot of people who are depressed, anxious and don’t have that mental drive. There’s a complete shift within hours and then you feel within several hours to a day that body heat increasing.
1:28:48
For a question for a post menopausal symptomatic woman using that to lose weight, they already have a problem with feeling hot. Does that just intensify it or do you know?
1:29:04
Well you know, we have had we have had women complain about you know, temp body temperature. I think in general it hasn’t hasn’t been something that we’ve seen that prolific and I think that what happens in this case is that you’re beginning to normalize body temperature beginning to normalize that feeling of like body temperatures up and you maybe don’t they don’t feel the fluctuations. But we’re not getting we’re not getting that. That response and that that adverse effect being reported at all. We’ve had a few that have said yeah, I’m warmer but it’s not intolerable. I’m fine.
Bill Clearfield 1:29:43
With Okay, so everybody knows what my next question is going to be. What are the effects on these products on on hormones that so does it have you have you looked
1:29:52
at? Well, yeah, you know, based on the targets of activity, we don’t see that there’s any effects on the hormones. However, you know, we don’t know the full gamut of the effects systemically. There shouldn’t be based on how they work. These are working at a metabolic level, not at a level where you know, hormones are being induced. However, I don’t want to be completely absolute about that, because we don’t know for sure. What I do know is that, you know, we’re not going to we’re not we’re not affecting the pituitary gland. We’re not affecting, you know, ACTH and adrenal glands. I can’t see it being a factor but we can
Bill Clearfield 1:30:38
say about the converting enzymes, the enzymes that create the chemical reactions that that sort of generate the hormones.
1:30:51
We are definitely, you know, seeing conversion in brown adipose fat. I don’t know how far I can’t, I can’t, I can’t comment beyond what we’re studying at the moment. And as we were just expanding the studies as we go, and reporting as we go, which, luckily speaks more than to how many pharmaceuticals are studied selectively. We’re just trying to we’re trying we’re expanding what we study as we
Bill Clearfield 1:31:19
go. Right, if I recall correctly, doesn’t resveratrol increased Brown. Convert white fat to brown fat.
1:31:30
white fat can’t be converted. But what I think what’s happened is there’s been a misunderstanding. There’s our beige fat. There’s beige fat embedded in white fat cells. Those are supposed to be active and those then become active in the in and you do have to take a lot of resveratrol to begin activation that doesn’t necessarily work against one of the things that actually inhibits these brown fat cells is subclinical inflammation. Many of the cytokines associated with inflammation TNF alpha specifically, contribute to the de escalation of uncoupling protein in these fats, which then shuts off thermogenic activity. In fact, I mentioned earlier, the common many decades ago the ECA stack ephedrine, caffeine, aspirin, aspirins role in that activity was the inhibition of Cox and production of prostaglandins that affected inflammatory activity. And that allowed then it allowed these compounds to work their wonders in terms of activating uncoupling protein. And in this case, we’re not requiring that because, you know, we’ve tried to eliminate what other synergistic activities we have to apply because adding another COX inhibitor would have had an another layer of adverse events.
Bill Clearfield 1:32:49
Can you give us a couple of other examples of supplements that are chemicals that you’ve worked with that that will increase thermogenesis?
1:33:01
We do have we do have another compound that showed very, very similar activity. Because once we activated these pathways, we begin to test a whole bunch of other compounds. We have another one we call thermo butyrate, which is the complexing of Chlorogenic Acid with the butyric acid, which affects the exact same enzymatic pathways, and that’s another compound we actually patented that as well. And we can actually bond them through a carboxylation bond and that creates a new molecule which is a drug or we can actually get the same effect by blending them.
Bill Clearfield 1:33:45
Okay, great. Okay, I think I’m cool.
1:33:51
Obviously, to keep us all keep us all treating people with these compounds, we sell it out as a blended compound, and then we’re going to do the clinical trials on a complex compound for the new drug. Okay.
Bill Clearfield 1:34:06
Great. All right. Well, I already call Jackie and told her I put my order in. So
1:34:11
I want to make one quick note to really quick regarding the dosing of the thermal formula. If you’re under 179, you only take one capsule, and if you’re overwhelmed every night they’ll take two so it can be very effective to make sure you only need you know, one bottle could last two months if you’re under under 179 pounds. So just wanted to make sure that note was made.
1:34:42
Yep, that’ll work. Okay.
Bill Clearfield 1:34:46
Okay. Anybody else have any questions? Pretty great. This was great. Dr. Calavera. Thank you so much. And I know it was a last minute thing so it it’s much appreciated.
1:35:00
It’s great. My pleasure. When I was commenting on oh my gosh, you guys want me to present I wasn’t I wasn’t backing out or anything. It was like, Wait a minute. These folks are gonna expect a formal presentation with everything. I thought it was just being interviewed. But I love this Fireside Chats the best way to go.
Bill Clearfield 1:35:17
We were not we’re not that formal here. So
1:35:23
anyways, I appreciate you folks taking the time to listen in. It’s my pleasure.
Bill Clearfield 1:35:28
Appreciate you. Oh, by the way, next week, everybody next week, same time, same station. We have our old friend Dr. Jeffrey block is back and he’s going to be giving us an update on an update on his world of cannabis including his he’s been testifying at the Florida State Legislature in different capacities but it’s uh you know, for legalizing things went out of state and national level so that’ll be next week. Okay. So, same time, same station. If you’re interested, Dr. Calavera will add you to our email list. And if you’re not I’d love to listen and we’ll make sure we’ll make sure you get the get the info we’re here every week. This this week, actually is three years we’ve been doing this every Tuesday except 103 years. Yeah.
1:36:24
Our outstanding job, Dr. Bill, so thank you.
Bill Clearfield 1:36:30
So you got a great, try to keep it we try to keep it you know interesting and you know, cutting edge. So next week, by the way, if you guys have nothing to do, I’m going to be in Houston at the age management Medical Group. Thursday the 19th I’m speaking on basic hormones for men and then on Sunday, I’m doing non hormonal manipulations to manipulate hormones. So how to how to how to raise your testosterone or how to lower your testosterone if need be without using testosterone. And we’re gonna go through a wall that will get the 10 major major hormones so you need some CME credits. It’s a really fun group. They’re really nice. They’re much, much less formal than a forum and we have a really good time with them. So and Stefan Hartman can vouch that he’s been there. So it Houston next week, it’s age med.org AG e FTD. O rg.org. And if you’re there, I think the the physician who the the male physician who takes eight milligrams of estradiol because he thinks Esther dial levels should be 200 for males. I think he’s speaking again to so you can question him
1:37:55
anyway. So it can’t be any worse than what I saw on the roster for a friend this serious like vegan brainwashing and Blake Blue Zones. I was like, I can’t go to this. Yeah. Is anyone going to that?
Bill Clearfield 1:38:10
I was going to go doctor and then you got Dr. Oz. Is there. Is there a keynote speaker too.
1:38:16
I saw that. Isn’t that guy like a shill for like the random is like infomercial stuff.
Bill Clearfield 1:38:26
Yeah, I guess I don’t know. So you want to Dr. calimary? Are we good here? I mean, we just don’t want to cut you off.
1:38:37
No, no, don’t worry about that. But I can tell you I can speak to the estrogen. You know, when we when we were bodybuilding when I was bodybuilding, we were very technical with with the application and in the last two years, I did do anabolics and we had to manage the aromatase activity and conversion of testosterone to estrogen before these events because the estrogen would cause water retention and you don’t want that. But I gotta tell you, as soon as you start dropping that estrogen activity with these inhibitors, you you feel terrible, and if you start studying that the estrogen is required for anti inflammatory activity to ensue. endogenously so there’s got to be something something just that speaks to that from the scientific standpoint, because that estrogen testosterone has to be balanced perfectly.
Bill Clearfield 1:39:22
Yeah, we know that. You know, when we first started doing this 20 years ago, we didn’t really have anything to go on. Except you. You gym rats didn’t know you were one of them. We would our goals were total testosterone of 1500 for and this is for guys, and and we will get to zero. And we I think we learned that that was you know, wrong and wrong. And yeah, but there’s a whole cadre of folks, especially at this conference, they last year in April, they they had four lectures on you do not let just let the estrogen rise that level doesn’t matter. Now. I’ve been doing this for 20 years. I’ve had 10,000 Men easily. I’ve treated when their estrogen levels go over, over 40 over 50 We get all sorts of side effects from it. And you know, I you know, we don’t get it to zero but to just let it rise to 250 175 is just crazy to me. I don’t know, I still wouldn’t
1:40:32
pay someone to hear mentioned the muscle loss with the semaglutide. And I was just during this call. I was making a prescription for just the fix for this. And it’s it’s anabolics it’s Oxandrolone and nandrolone. These things protect you against from that muscle that loss
1:40:49
because they activate mTOR that’s what they’re doing. We had a bollocks, the anabolic drive mechanisms or mTOR activation to induce protein synthesis.
Bill Clearfield 1:41:00
We’ve been using creatine also so
1:41:03
injectable carnitine. All there and then the anabolics testosterone oxy Angela and and nandrolone and, you know, obviously the US
1:41:15
was I do prescribe to I work. I work for my own. I take testosterone and and a small amount of an estrogen blocker through glow clinic I take an anti aging program. Formally, I just did bloodwork today, every 60 days, I do bloodwork for them to monitor it, but I have to say like I’ve never felt better my life and I never thought I would do this again. But at my age it was something obviously that that was something I would see to that I may do. In the last two and a half years. I did go to hormone therapy and take a TRT with an estrogen blocker I take twice a week. And growth hormone. So yeah, I feel I feel unbelievably amazing.
Bill Clearfield 1:41:58
Yeah, that’s pretty much you know, the regimen that we usually we find total testosterone 700 to 900 is usually pretty ideal. Anything over over that is we’re gonna see side effects without any real benefit. So ideally 15 to 25 Anything over 40 we want to we want to control it. I mean, that’s that’s kind of what we’ve been doing. But like I said, you know, there’s one guy, he’s doing pellets, he’s gets the testosterone levels to 2020 200 and estrogens to, he said his was great, Steve, you were there. 175 I think he said, right. Yeah, he had no problem with that study was the time before he dropped his zester dial intake from eight milligrams a day to seven. I did notice that I did pick up on that. So I mean, we don’t we don’t treat postmenopausal women with seven milligrams of estradiol, at least I know.
1:42:55
She’s talking about what about hematocrit when he’s taken that level of testosterone at that age.
Bill Clearfield 1:43:02
It’ll go up. So actually, that I’m not all that all that concerned about you know, as long as the you know, it’s not a platelets in the white count are normal in America. Usually, the only reason we lower it is for in societies sake, but technically you know, you’re not going to get blood clotting from the doctor. Come to the lecture on next week. You’ll see I have the statistics therefore.
1:43:36
Well, you know what, I was writing it down because I’m very interested. I’d like to come because I’ve just, I tell you, you know, when I when I did anabolics for the show, I was monitored intensely. But that was for a different reason. Today I’m older I’m trying to maintain health. And it was I never did growth hormone when I was when I was training for those shows. It was just, you know, anabolics taking some testosterone and a few other designer anabolics but, and that is if my I look back now and you know, I got away with with a lot because the weights were lifting the stuff we did to our body. Nevertheless, today being monitored. I’m really watching every single marker to make sure we’re okay. And I did have hematocrit levels go up a little bit, so I had to phlebotomist during the course, to make sure I brought it down. It seems to be fine now, but you’re saying that that’s not something you’re concerned with with your patients at the moment
Bill Clearfield 1:44:28
though the patients get they see on the lab slip that it’s flagged highs. But the the clotting factors don’t change with testosterone and the statistics as far as a heart attack, you know, coronary occlusions cerebral cerebral occlusions are no different than with placebo. So and I can get you the literature on that if
1:44:58
you want. Interesting. Yeah, that sounds great. I wanted to ask you to step on. I’ve seen you using Dr. Jock wishes armbands before physical therapy and I’m get ready for that setup myself. But osteo strong they’re the franchise that has the osteo strong process for building up bone strength. Have you looked into any of that?
1:45:24
He has a vibration plate that he sells. It’s not
1:45:27
just a vibration plate. He actually 10 to 15 seconds once a week. You do a push. You do a pull you pull up and you do the leg strength and they’re having huge results and what’s his name? Tony Robbins spent
1:45:44
prolonged time under tension with that and that’s pretty cool. I like that correct. We’re experimenting is vide play now at the office here. My dad really likes he’s grown a lot of muscle doing that thing. From here. He’s also taking mk 677
1:46:05
better by a lot No,
Bill Clearfield 1:46:12
but you know I have a suspicion that it’ll be gone. It’ll it’ll straighten itself out at some point is one of these kind of opening salvo kind of things so. And that’s just my own. My own. I’m trying to find the statistics here for you. So you guys talk amongst yourselves and I’ll find it here.
1:46:40
All right. Can I be heard as you can. Okay, two months ago went on his epic wiped me out. Side effects were horrific. So I got like three shots in right skipped a week then another week tried to every time wipe me out. Made me feel like I was dying, right? Really bad. And so anyway, just started the another one of those things manure is it on Jarrow on you’re on Joe way anyway, same side effect same symptoms wipe me out. I’ve only done it once. And I’m afraid to do it twice. So just thought I would mention that. And I could show you my good number. It’s 147 Man, that’s pretty cool. But the side effects are horrific. So all of this are pretty important issues. And without these drugs, the sugar goes up 100 points. So
1:47:41
that’s you know what I mean? He does
Bill Clearfield 1:47:44
I think I think you need some of our some of our adulterated stuff so like I said, we we put in BPC 157 We put in B six. We we use tiny dose micro doses five days a week instead of a once a week shot. And then we have our patient all of our patients now. I don’t know I hit on this I don’t even know where I came on. A Well, our patients we make them get fresh ginger. And our discontinuation rate went down from the drug companies is 44%. Ours was less than 4%. We’ve had two patients in the last four months and we’re seeing at least five a day. New ones a day.
1:48:28
There you go. The drug works brings the sugar down but the side effects can be killer.
Bill Clearfield 1:48:33
So I’m telling you, I’m telling you I’m telling you how to get around it. Anyway. So can you see the screen here? I can Yes, yeah. This is polysafe fimea Vera vs. Faster reduce vascular complications. And so here’s blood clot general population, cerebral vascular accidents 5.3 per 1000. Testosterone slightly more than 6.2 versus poli sci theory at 14.3. So slightly, it’s like just a slight it’s not really even statistically significant. But look at the heart attacks, actually less than a general population and DVT is also less than a general population. And if you want to do the do the math here, especially for blood clots, if you want to fool them, you see it’s 20% less, you know, it’s two, it’s two patients less but it’s 20. Okay, here’s the references here for you. So,
1:49:26
yeah, that’s amazing. It’s good to know.
Bill Clearfield 1:49:28
Okay, and so and then, you know, so the blood clotting. So polysafe dini, Aveiro, first of all, is one of the rare drugs rare disease list. It’s really not very common. It’s a bone marrow tumor. It’s genetically 97%. Not genetically induced with the J K two and Te T two mutations. Testosterone doesn’t do that. EPO is low with volleys idemia versus high without you get your blood clots, strokes and whatnot. You get increased white cells and platelets. Um, you all you need to do is look at a CBC to to know what it is. That’s all you need to know. Yeah. So this is part of the talk. We’re doing. Well, I’m doing next week, so So this is
1:50:13
in in Texas,
Bill Clearfield 1:50:15
in Texas in Houston. Yeah.
1:50:17
All right. I’m gonna take an emergency run out there.
Bill Clearfield 1:50:21
If you’re interested, go to H ER.
1:50:23
I’ll put it in there
1:50:24
for H med.org. I got that written down already for you.
Bill Clearfield 1:50:27
red.org. So
1:50:29
yeah. Hey, we
1:50:32
got to be polite. It’s Doctor have Larry not have calorie very or it’s
1:50:41
I’ve been I’ve been called a lot worse as we
1:50:45
think of him as as a horse. He’s a cab. Cab, Kevin. Larry said respect for this man. Give the name right.
1:50:57
That’s okay. It’s good. Okay. Thank you so much, gentlemen. I appreciate you.
1:51:03
Thank you, everybody.
1:51:05
John, has a medical school. Everything’s wonderful. Beautiful. I need to talk to you before you take off though. All right, not tonight, but sometime, so things are good. Things are good.
Bill Clearfield 1:51:15
All right. Great. All right. Can I get everybody Dr. Block?
1:51:20
Yeah. Did he want me to make a few remarks about? Yeah, we’re having a meeting on the 18th. I sent that meeting detail to bill he can he can send out to everyone. We’re discussing a parallel health system, creating a network of medical offices, pharmacies, own imaging centers, laboratories around licensing. Basically everything to separate us from the current medical system which is now banning peptides which we’re all fans of peptides, right we know that’s a profit move on. Big Pharma, corrupt FDA the whole link there. So if you’re interested in separating yourself from the corrupt medical industrial complex, please join the meeting and to learn more on the 18th
Bill Clearfield 1:52:05
I think it was the night wasn’t it? The 19th 19th
1:52:08
Okay, I forget some of the details that everyone
1:52:10
you guys are all intense.
Bill Clearfield 1:52:14
Okay, anything else? Hey, John. Did you go to omit at least the at least the
1:52:22
math this is the only group I deal with right here. I am spoiled.
1:52:27
I’m good with this. Okay. All right.
Bill Clearfield 1:52:30
So all right. So
1:52:32
what was the email Stefan that you sent? It wasn’t under on your direct primary care, right.
1:52:37
It was pretty sure I sent it to you, too.
1:52:39
You’ll you did you did I’m just looking for it. And it’s it’s not under the iron
1:52:44
drawer. I know. It’s under iron medicine pa@gmail.com That’s what I use for professional.
Bill Clearfield 1:52:49
Other ones relations. Okay, perfect. Good. Okay. All right. Thanks, everybody. Thanks, Stefan.
1:52:59
Have a good night. But
Bill Clearfield 1:53:03
no answer etc. Cut the cut off. Okay, John.
1:53:07
Say hello to Sylvia. All right. Thanks. Bye. Good night, everybody.
Bill Clearfield 1:53:10
Jackie, thank you. If you’re still on everybody else, we’ll see you again. I’ll have this up as soon as I can. And that’s it. Goodnight, everybody.